The interactions of LNEO with DNA and the PI3K/mTOR dual inhibitor indicate that LNEO-loaded PLGA NPs have the potential to be used in cancer therapy as a novel phytotherapeutic agent-based controlled-release system. This evidence concerns the gene MTOR and cancer.